Daiichi Sankyo (OTCPK:DSNKY) has entered into a strategic agreement with Syneos Health (SYNH +1.0%) to form a coalition for development of cancer therapies.
Under the agreement, Syneos Health will provide
both strategic and operational solutions for three lead Daiichi Sankyo
DXd antibody drug conjugates (ADC): DS-1062, U3-1402 and DS-8201 (known
as ENHERTU).
The coalition will further leverage Syneos
Health’s Syneos One product development model to de-risk and accelerate
development and also enable early strategic engagement of Syneos Health
teams to inform critical drug development decision making from the
start.
https://seekingalpha.com/news/3578280-daiichi-sankyo-and-syneos-health-collaborate-to-develop-oncology-pipeline
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.